Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance

British Journal of Radiology

Volumn 84, Issue 997, 2011, Pages 31-37

  Morgan, V A ^a   Riches, S F ^a   Thomas, K ^b   Vanas, N ^c   Parker, C ^c   Giles, S ^a   Desouza, N M ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b Department of Statistics ^*  (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

APPARENT DIFFUSION COEFFICIENT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; ECHO PLANAR IMAGING; GLEASON SCORE; HUMAN; MALE; PROGNOSIS; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO;

DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; HUMANS; MALE; NEOPLASM STAGING; PROSTATE; PROSTATIC NEOPLASMS; WATCHFUL WAITING;

EID: 78650642291     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/14556365     Document Type: Article

References (21)

1. Casciani E, Polettini E, Bertini L, Emiliozzi P, Amini M, Pansadoro V, et al. Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol Med 2004;108:530-41.
2. Kirkham AP, Emberton M, Allen C. How good is MRI at detecting and characterising cancer within the prostate? Eur Urol 2006;50:1163-74.
3. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000; 92:2029-36.
4. Lo GG, Ai V, Chan JK, Li KW, Cheung PS, Wong TT, et al. Diffusion-weighted magnetic resonance imaging of breast lesions: first experiences at 3 T. J Comput Assist Tomogr 2009;33:63-9.
5. Messiou C, Morgan VA, De Silva SS, Ind TE, deSouza NM. Diffusion weighted imaging of the uterus: regional ADC variation with oral contraceptive usage and comparison with cervical cancer. Acta Radiol 2009;50:696-701.
6. Somford DM, Futterer JJ, Hambrock T, Barentsz JO. Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am 2008;16:685-95.
7. Uto T, Takehara Y, Nakamura Y, Naito T, Hashimoto D, Inui N, et al. Higher sensitivity and specificity for diffusionweighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology 2009; 252:247-54.
8. Shimofusa R, Fujimoto H, Akamata H, Motoori K, Yamamoto S, Ueda T, et al. Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 2005;29:149-53.
9. Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Korogi Y, et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 2006;27:1419-25.
10. deSouza NM, Riches SF, Vanas NJ, Morgan VA, Ashley SA, Fisher C, et al. Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008;63: 774-82.
11. van As NJ, deSouza NM, Riches SF, Morgan VA, Sohaib SA, Dearnaley DP, et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol 2008 [Epub ahead of print].
12. Riches SF, Hawtin K, Charles-Edwards EM, deSouza NM. Diffusion-weighted imaging of the prostate and rectal wall: comparison of biexponential and monoexponential modelled diffusion and associated perfusion coefficients. NMR Biomed 2009;22:318-25.
13. Kelly IM, Lees WR, Rickards D. Prostate cancer and the role of color Doppler US. Radiology 1993;189:153-6.
14. Rifkin MD, Sudakoff GS, Alexander AA. Prostate: techniques, results and potential applications of color Doppler US scanning. Radiology 1993;186:509-13.
15. Parker C, Milosevic M, Toi A, Sweet J, Panzarella T, Bristow R, et al. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004;58:750-7.
16. Butterworth KT, McCarthy HO, Devlin A, Ming L, Robson T, McKeown SR, et al. Hypoxia selects for androgen independent LNCaP cells with a more malignant genoand phenotype. Int J Cancer 2008;123:760-8.
17. Kitajima K, Kaji Y, Kuroda K, Sugimura K. High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-tonoise ratio. Magn Reson Med Sci 2008;7:93-9.
18. Zelhof B, Pickles M, Liney G, Gibbs P, Rodrigues G, Kraus S, et al. Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer. BJU Int 2009;103:883-8.
19. Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98:1521-7.
20. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004;351: 125-35.
21. D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 2005;294:440-7.